Behind the Guidelines: Top Clinical Takeaways From the 2026 Dyslipidemia Guidelines

The 2026 ACC/AHA Dyslipidemia Guideline represents a transformative advance in cardiovascular risk management, which the organizations hope clinicians can navigate effectively by anchoring to a focused set of key principles cutting across the guideline's extensive breadth.

Pamela B. Morris, MD, vice chair of the writing committee, and Ann Marie Navar, MD, PhD, close the HCPLive Special Report series with a synthesis of the most clinically actionable updates. At the core of the guideline is a transition from the Pooled Cohort Equations to the AHA PREVENT equations, providing more accurate absolute risk estimates and enabling risk assessment beginning at age 30. When treatment decisions remain uncertain in borderline-to-intermediate risk patients, the Calculate-Personalize-Reclassify model using coronary artery calcium (CAC) scoring offers a structured framework for individualized decision-making. Any nonzero CAC score signals subclinical atherosclerosis and triggers risk-stratified treatment goals; a score above 300 approaches the risk profile of secondary prevention, and a score above 1,000 warrants very high-risk management.

Universal Lp(a) measurement, at least once in all adults, is now a Class I recommendation, alongside the first-ever US guideline inclusion of apolipoprotein B for selected populations.

Absolute LDL cholesterol goals have been restored:

• Less than 55 mg/dL for very high-risk patients
• Less than 70 mg/dL for high-risk individuals
• Less than 100 mg/dL for primary prevention

With the principle lower is always better applied across all risk categories.

The therapeutic armamentarium has expanded substantially since 2018. Beyond statins and ezetimibe, clinicians now have access to bempedoic acid, PCSK9 monoclonal antibodies, inclisiran, and, for select populations, evinacumab and APOC3 inhibitors. As Navar summarizes, patients and clinicians alike can orient around three numbers, 55, 70, and 100, as guiding targets for the highest-risk, intermediate, and lower-risk groups, respectively. The tools to achieve LDL goals for even the most complex patients now exist; the priority must shift to ensuring those tools are applied.

Morris has no relevant disclosures to report. Navar reports disclosures with Amge, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly and Company, Esperion, Johnson & Johnson, Merck, Miga Health, NewAmsterdam Pharma, Novartis, Novo Nordisk, Sanofi, and Silence Therapeutics, among others.

References:

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
2. American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology. American College of Cardiology. Published March 13, 2026. Accessed March 23, 2026. https://www.acc.org/About-ACC/Press-Releases/2026/03/13/18/01/ACCAHA-Issue-Updated-Guideline-for-Managing-Lipids-Cholesterol